Skip to main content

Advertisement

SpringerLink
Log in

Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation

  • Original Article
  • Published:
Tumor Biology

Abstract

Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related death worldwide. Patients presenting with advanced-stage NSCLC have poor prognosis, while metastatic spread accounts for >70 % of patient’s deaths. The major advances in the treatment of lung cancer have brought only minor improvements in survival; therefore, novel strategic treatment approaches are urgently needed. Accumulating data allocate a central role for the cancer microenvironment including mesenchymal stem cells (MSCs) in acquisition of drug resistance and disease relapse. Furthermore, studies indicate that translation initiation factors are over expressed in NSCLC and negatively impact its prognosis. Importantly, translation initiation is highly modulated by microenvironmental cues. Therefore, we decided to examine the effect of bone marrow MSCs (BM-MSCs) from normal donors on NSCLC cell lines with special emphasis on translation initiation mechanism in the crosstalk. We cultured NSCLC cell lines with BM-MSC conditioned media (i.e., secretome) and showed deleterious effects on the cells’ proliferation, viability, death, and migration. We also demonstrated reduced levels of translation initiation factors implicated in cancer progression [eukaryotic translation initiation factor 4E (eIF4E) and eukaryotic translation initiation factor 4GI (eIF4GI)], their targets, and regulators. Finally, we outlined a mechanism by which BM-MSCs’ secretome affected NSCLC’s mitogen-activated protein kinase (MAPK) signaling pathway, downregulated the cell migration, and diminished translation initiation factors’ levels. Taken together, our study demonstrates that there is direct dialogue between the BM-MSCs’ secretome and NSCLC cells that manipulates translation initiation and critically affects cell fate. We suggest that therapeutic approach that will sabotage this dialogue, especially in the BM microenvironment, may diminish lung cancer metastatic spread and morbidity and improve the patient’s life quality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest. 2007;117:2740–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Higgins MJ, Ettinger DS. Chemotherapy for lung cancer: the state of the art in 2009. Expert Rev Anticancer Ther. 2009;9:1365–78.

    Article  PubMed  Google Scholar 

  3. Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Perez-Soler R, et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res. 2007;67:11300–8.

    Article  CAS  PubMed  Google Scholar 

  4. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46.

    Article  CAS  PubMed  Google Scholar 

  5. Graves EE, Maity A, Le QT. The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:156–63.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Liu R, Wei S, Chen J, Xu S. Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Lett. 2014;353:145–52.

    Article  CAS  PubMed  Google Scholar 

  7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

    Article  CAS  PubMed  Google Scholar 

  8. Korkaya H, Wicha MS. Breast cancer stem cells: we’ve got them surrounded. Clin Cancer Res. 2013;19:511–3.

    Article  CAS  PubMed  Google Scholar 

  9. Klaus M, Stavroulaki E, Kastrinaki MC, Fragioudaki P, Giannikou K, Psyllaki M, et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2010;19:1043–54.

    Article  CAS  PubMed  Google Scholar 

  10. Gottschling S, Granzow M, Kuner R, Jauch A, Herpel E, Xu EC, et al. Mesenchymal stem cells in non-small cell lung cancer—different from others? Insights from comparative molecular and functional analyses. Lung Cancer. 2013;80:19–29.

    Article  PubMed  Google Scholar 

  11. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol. 2006;198:54–64.

    Article  CAS  PubMed  Google Scholar 

  12. Kim S, Kim HS, Lee E, Kim HO. In vivo hepatic differentiation potential of human cord blood-derived mesenchymal stem cells. Int J Mol Med. 2011;27:701–6.

    Article  PubMed  Google Scholar 

  13. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010;10:254–66.

    Article  CAS  PubMed  Google Scholar 

  14. Barnhart B, Simon M. Taking aim at translation for tumor therapy. J Clin Invest. 2007;117:2385–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Thornton S, Anand N, Purcell D, Lee J. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med. 2003;81:536–48.

    Article  CAS  PubMed  Google Scholar 

  16. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol. 2007;136:565–73.

    Article  CAS  PubMed  Google Scholar 

  17. Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, et al. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 2012;13:272–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bauer C, Brass N, Diesinger I, Kayser K, Grasser FA, Meese E. Overexpression of the eukaryotic translation initiation factor 4G (EIF4G-1) in squamous cell lung carcinoma. Int J Cancer. 2002;98:181–5.

    Article  CAS  PubMed  Google Scholar 

  19. Zismanov V, Drucker L, Gottfried M. ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors. Pulm Pharmacol Ther. 2013;26:388–94.

    Article  CAS  PubMed  Google Scholar 

  20. Zismanov V, Drucker L, Gottfried M. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration. Anti Cancer Drugs. 2014;25:998–1006.

    Article  CAS  PubMed  Google Scholar 

  21. Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther. 2002;1:971–9.

    CAS  PubMed  Google Scholar 

  22. Jacobson BA, Alter MD, Kratzke MG, Frizelle SP, Zhang Y, Peterson MS, et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res. 2006;66:4256–62.

    Article  CAS  PubMed  Google Scholar 

  23. Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments trail-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia. 2010;12:346–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zismanov V, Lishner M, Tartakover-Matalon S, Radnay J, Shapiro H, Drucker L. Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer. 2009;101:1402–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Rashid G, Lishner M. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Investig. 2012;92:178–90.

    Article  CAS  PubMed  Google Scholar 

  26. O’Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J. 2008;409:635–49.

    Article  PubMed  Google Scholar 

  27. Dolfi SC, Chan LL, Qiu J, Tedeschi PM, Bertino JR, Hirshfield KM, et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab. 2013;1:20.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Zismanov V, Drucker L, Attar-Schneider O, Matalon ST, Pasmanik-Chor M, Lishner M. Tetraspanins stimulate protein synthesis in myeloma cell lines. J Cell Biochem. 2012;113:2500–10.

    Article  CAS  PubMed  Google Scholar 

  29. Robert F, Pelletier J. Translation initiation: a critical signalling node in cancer. Expert Opin Ther Targets. 2009;13:1279–93.

    Article  CAS  PubMed  Google Scholar 

  30. Yang YJ, Zhang YL, Wang JD, Lai ZS, Wang QY, Cui HH. [Role of eukaryotic initiation factor-4E (eIF-4E) in regulation of expression of NF-kappaB and its subsequent influence on transcription and activity of heparanase in human colon adenocarcinoma cell line]. Ai Zheng. 2003;22:1023–9.

    CAS  PubMed  Google Scholar 

  31. Shiroki K, Ohsawa C, Sugi N, Wakiyama M, Miura K, Watanabe M, et al. Internal ribosome entry site-mediated translation of Smad5 in vivo: requirement for a nuclear event. Nucleic Acids Res. 2002;30:2851–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Baird SD, Turcotte M, Korneluk RG, Holcik M. Searching for IRES. RNA. 2006;12:1755–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007;28:501–12.

    Article  CAS  PubMed  Google Scholar 

  34. Kaiser C, Dobrikova EY, Bradrick SS, Shveygert M, Herbert JT, Gromeier M. Activation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo. RNA. 2008;14:2170–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lau MT, So WK, Leung PC. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 2013;8:e59083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Shveygert M, Kaiser C, Bradrick SS, Gromeier M. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. Mol Cell Biol. 2010;30:5160–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ampollini L, Madeddu D, Falco A, Frati C, Lorusso B, Graiani G, et al. Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cellsdagger. Eur J Cardiothorac Surg. 2014;46:e103–12.

    Article  PubMed  Google Scholar 

  38. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–52.

    Article  CAS  PubMed  Google Scholar 

  39. Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol. 2011;6:576–82.

    Article  PubMed  Google Scholar 

  40. Roato I. Bone metastases: when and how lung cancer interacts with bone. World J Clin Oncol. 2014;5:149–55.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Campolo F, Gori M, Favaro R, Nicolis S, Pellegrini M, Botti F, et al. Essential role of Sox2 for the establishment and maintenance of the germ cell line. Stem Cells. 2013;31:1408–21.

    Article  CAS  PubMed  Google Scholar 

  42. Fernandez Vallone VB, Hofer EL, Choi H, Bordenave RH, Batagelj E, Feldman L, et al. Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis. Clin Exp Metastasis. 2013;30:317–32.

    Article  PubMed  Google Scholar 

  43. Redzic JS, Balaj L, van der Vos KE, Breakefield XO. Extracellular RNA mediates and marks cancer progression. Semin Cancer Biol. 2014;28:14–23.

    Article  CAS  PubMed  Google Scholar 

  44. Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci. 2014;15:4142–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One. 2013;8:e84256.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Attar-Schneider O, Zismanov V, Dabbah M, Tartakover-Matalon S, Drucker L, Lishner M. Multiple myeloma and bone marrow mesenchymal stem cells’ crosstalk: effect on translation initiation. Mol Carcinog. 2015. doi:10.1002/mc.22378.

    PubMed  Google Scholar 

  47. Boomsma RA, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One. 2012;7:e35685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Nasr Z, Pelletier J. Tumor progression and metastasis: role of translational deregulation. Anticancer Res. 2012;32:3077–84.

    CAS  PubMed  Google Scholar 

  49. Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010;70:3780–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors’ contribution

The authors’ contributions were as follows: Attar-Schneider and Zismanov were responsible for the conception and design of the study, acquisition, analysis and interpretation of data, and drafting the article. Drucker and Gottfried were responsible for the conception and design of the study and for final approval of the version to be submitted.

Author information

Author notes

    Authors and Affiliations

    1. Lung Cancer Research, Meir Medical Center, Kfar Saba, 44281, Israel

      Oshrat Attar-Schneider, Victoria Zismanov & Maya Gottfried

    2. Oncogenetic Laboratories, Meir Medical Center, Kfar Saba, 44281, Israel

      Oshrat Attar-Schneider & Liat Drucker

    3. Oncology Department, Lung Cancer Unit, Meir Medical Center, Kfar Saba, 44281, Israel

      Maya Gottfried

    4. Sackler Faculty of Medicine, Tel Aviv University Ramat Aviv, Tel Aviv, 69978, Israel

      Oshrat Attar-Schneider, Victoria Zismanov, Liat Drucker & Maya Gottfried

    Authors
    1. Oshrat Attar-Schneider
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Victoria Zismanov
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Liat Drucker
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Maya Gottfried
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Oshrat Attar-Schneider.

    Ethics declarations

    Conflicts of interest

    None

    Additional information

    Oshrat Attar-Schneider and Victoria Zismanov contributed equally to this work.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    ESM 1

    (PDF 210 kb)

    ESM 2

    (PDF 227 kb)

    ESM 3

    (PDF 264 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Attar-Schneider, O., Zismanov, V., Drucker, L. et al. Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation. Tumor Biol. 37, 4755–4765 (2016). https://doi.org/10.1007/s13277-015-4304-3

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-4304-3

    Keywords

    Search

    Navigation